FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3142666124> ?p ?o ?g. }

• W3142666124 abstract "Background: Clinical trials for antiparkinsonian drugs aimed at managing motor complications typically use patient diaries to divide levodopa-induced dyskinesias (LID) into “troublesome” and “non-troublesome” categories. Yet, given the choice, most patients would prefer to live without experiencing any dyskinesia. However, the concept of evaluating time spent ON without any dyskinesia as an outcome has never been tested. We conducted analyses of pooled Gocovri pivotal trial data in order to evaluate the extent to which Gocovri increased the time PD patients spent ON without dyskinesia (troublesome or non-troublesome), beyond its already identified improvement in reducing troublesome dyskinesia. Methods: Patients enrolled in phase 3 trials (EASE LID [NCT02136914] or EASE LID 3 [NCT02274766]) recorded time spent in the following PD diary states at baseline and Week 12 (endpoint): asleep, OFF, ON with troublesome dyskinesia, ON with non-troublesome dyskinesia, and ON without dyskinesia. Mixed model repeated measures analyses with estimated Cohen D effect sizes were performed on the modified intent to treat population to evaluate changes in time spent in these states. Results: Patients randomized to receive Gocovri showed an increase in ON time without dyskinesia and corresponding decreases in ON time with dyskinesia and OFF time vs. placebo. Treatment effects were statistically significant for Gocovri vs. placebo starting at Week 2 and were sustained until Week 12. On MMRM analysis at Week 12, patients in the Gocovri group showed an adjusted mean ± SE increase over placebo of 2.9 ± 0.6 h in ON time without dyskinesia (Cohen D effect size 0.79) and an adjusted mean ± SE decrease of −1.9 ± 0.6 h in ON time with dyskinesia (troublesome + non-troublesome) (Cohen D effect size 0.49), that included a −1.5 ± 0.4 h placebo-adjusted reduction in ON time with troublesome dyskinesia and a −0.6 ± 0.4 h reduction in ON time with non-troublesome dyskinesia. OFF time was reduced by −1.0 ± 0.3 h compared to placebo. Conclusions: Gocovri treatment more than doubled the daily time patients spent ON without dyskinesia. These results suggest that the Gocovri treatment effect was driven by a reduction in overall motor complications including ON time with both troublesome and non-troublesome dyskinesia as well as time spent OFF." @default.
• W3142666124 created "2021-04-13" @default.
• W3142666124 creator A5009117789 @default.
• W3142666124 creator A5009430052 @default.
• W3142666124 creator A5057886606 @default.
• W3142666124 creator A5080057970 @default.
• W3142666124 creator A5086109424 @default.
• W3142666124 date "2021-03-26" @default.
• W3142666124 modified "2023-09-27" @default.
• W3142666124 title "Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease" @default.
• W3142666124 cites W1972389166 @default.
• W3142666124 cites W1988357251 @default.
• W3142666124 cites W1989607974 @default.
• W3142666124 cites W2005005374 @default.
• W3142666124 cites W2034825135 @default.
• W3142666124 cites W2035942308 @default.
• W3142666124 cites W2044590002 @default.
• W3142666124 cites W2078208735 @default.
• W3142666124 cites W2098736662 @default.
• W3142666124 cites W2115222037 @default.
• W3142666124 cites W2129848379 @default.
• W3142666124 cites W2140978740 @default.
• W3142666124 cites W2218385786 @default.
• W3142666124 cites W2343290709 @default.
• W3142666124 cites W2610902102 @default.
• W3142666124 cites W2621548695 @default.
• W3142666124 cites W2747038847 @default.
• W3142666124 cites W2760198391 @default.
• W3142666124 cites W2789703631 @default.
• W3142666124 cites W2889978819 @default.
• W3142666124 cites W2936450015 @default.
• W3142666124 cites W3000695970 @default.
• W3142666124 cites W3008592258 @default.
• W3142666124 cites W3011108060 @default.
• W3142666124 cites W3016658221 @default.
• W3142666124 cites W4249936768 @default.
• W3142666124 cites W75007412 @default.
• W3142666124 doi "https://doi.org/10.3389/fneur.2021.645706" @default.
• W3142666124 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8032973" @default.
• W3142666124 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33841311" @default.
• W3142666124 hasPublicationYear "2021" @default.
• W3142666124 type Work @default.
• W3142666124 sameAs 3142666124 @default.
• W3142666124 citedByCount "15" @default.
• W3142666124 countsByYear W31426661242021 @default.
• W3142666124 countsByYear W31426661242022 @default.
• W3142666124 countsByYear W31426661242023 @default.
• W3142666124 crossrefType "journal-article" @default.
• W3142666124 hasAuthorship W3142666124A5009117789 @default.
• W3142666124 hasAuthorship W3142666124A5009430052 @default.
• W3142666124 hasAuthorship W3142666124A5057886606 @default.
• W3142666124 hasAuthorship W3142666124A5080057970 @default.
• W3142666124 hasAuthorship W3142666124A5086109424 @default.
• W3142666124 hasBestOaLocation W31426661241 @default.
• W3142666124 hasConcept C126322002 @default.
• W3142666124 hasConcept C142724271 @default.
• W3142666124 hasConcept C15744967 @default.
• W3142666124 hasConcept C168563851 @default.
• W3142666124 hasConcept C1862650 @default.
• W3142666124 hasConcept C204787440 @default.
• W3142666124 hasConcept C27081682 @default.
• W3142666124 hasConcept C2777374534 @default.
• W3142666124 hasConcept C2779134260 @default.
• W3142666124 hasConcept C2779734285 @default.
• W3142666124 hasConcept C2780304432 @default.
• W3142666124 hasConcept C2780405171 @default.
• W3142666124 hasConcept C2908647359 @default.
• W3142666124 hasConcept C42219234 @default.
• W3142666124 hasConcept C71924100 @default.
• W3142666124 hasConcept C98274493 @default.
• W3142666124 hasConcept C99454951 @default.
• W3142666124 hasConceptScore W3142666124C126322002 @default.
• W3142666124 hasConceptScore W3142666124C142724271 @default.
• W3142666124 hasConceptScore W3142666124C15744967 @default.
• W3142666124 hasConceptScore W3142666124C168563851 @default.
• W3142666124 hasConceptScore W3142666124C1862650 @default.
• W3142666124 hasConceptScore W3142666124C204787440 @default.
• W3142666124 hasConceptScore W3142666124C27081682 @default.
• W3142666124 hasConceptScore W3142666124C2777374534 @default.
• W3142666124 hasConceptScore W3142666124C2779134260 @default.
• W3142666124 hasConceptScore W3142666124C2779734285 @default.
• W3142666124 hasConceptScore W3142666124C2780304432 @default.
• W3142666124 hasConceptScore W3142666124C2780405171 @default.
• W3142666124 hasConceptScore W3142666124C2908647359 @default.
• W3142666124 hasConceptScore W3142666124C42219234 @default.
• W3142666124 hasConceptScore W3142666124C71924100 @default.
• W3142666124 hasConceptScore W3142666124C98274493 @default.
• W3142666124 hasConceptScore W3142666124C99454951 @default.
• W3142666124 hasFunder F4320315817 @default.
• W3142666124 hasLocation W31426661241 @default.
• W3142666124 hasLocation W31426661242 @default.
• W3142666124 hasOpenAccess W3142666124 @default.
• W3142666124 hasPrimaryLocation W31426661241 @default.
• W3142666124 hasRelatedWork W1970320862 @default.
• W3142666124 hasRelatedWork W2443034916 @default.
• W3142666124 hasRelatedWork W2789738378 @default.
• W3142666124 hasRelatedWork W2972225004 @default.
• W3142666124 hasRelatedWork W3008592258 @default.
• W3142666124 hasRelatedWork W4206871429 @default.
• W3142666124 hasRelatedWork W4241238407 @default.

• next